Boosting Performance: The Power of Cranberry Supplementation

NCT06186297 | Completed

• 1 other identifier: 30017882
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 1

Brief Summary

Cranberry is a fruit native to North America that is widely grown in Quebec and has been shown to have the highest antioxidant capacity among the most commonly eaten fruits. Consequently, consuming cranberries prior to exercising may help to improve exercise endurance by preventing accumulation of reactive oxygen species. For aerobic endurance, in order to maintain a certain pace for a long duration, runners need to effectively neutralize reactive oxygen species. Although it is not the only component involved in running, offsetting reactive oxygen species should improve running performance. To test this, we plan to investigate the effects, both acute and chronic, of a cranberry extract on the oxygen consumption in 18-35 year old males and females. The present research project will contribute to expand our knowledge of how cranberry extract can exert a positive effect, and thus improve aerobic performance or even every day life. This project can benefit a wide range of the population, from sedentary individuals and older adults to elite athletes by providing an all-natural supplement alternative.

Conditions

Oxygen Consumption; Mitochondria; Blood Flow; Aerobic Capacity

Outcome Measures

Primary Outcomes (1)

• Oxygen consumption

  20 minutes

Secondary Outcomes (1)

• Blood flow

  20 minutes

Study Arms (2)

Cranberry extract

EXPERIMENTAL

Dietary Supplement: Cranberry extract

Baseline

ACTIVE COMPARATOR

Dietary Supplement: Cranberry extract

Interventions

Cranberry extract DIETARY_SUPPLEMENT

polyphenol PAC-1

Baseline; Cranberry extract

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• recreationally active, healthy and between the ages of 18-35.

You may not qualify if:

• smoker; use of ergogenic substances or any kind or drugs that could alter the cardiovascular responses; resting BP higher than 140/90 mm Hg; and cardiovascular or metabolic disease (especially hypertension and diabetes)

Sponsors & Collaborators

• Concordia University, Montreal: lead

Study Sites (1)

Concordia University

Montreal, Quebec, H4B 1R6, Canada

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: December 15, 2023
• First Posted: January 2, 2024
• Study Start: March 1, 2023
• Primary Completion: June 30, 2023
• Study Completion: June 30, 2023
• Last Updated: January 2, 2024

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)